StreetAlpha.app
Home › Stocks › NGNE

Neurogene Inc. (NGNE)

$23.10
▼ −0.86%
LAST CLOSE · NOV 17

Neurogene develops genetic medicines for rare neurological diseases, with its lead candidate aimed at Rett syndrome. It last closed at $23.10 on Nov 17, down 0.86% on the day. The average 12-month price target from 2 analysts is $60.00 (+159.7% from the last close), with a high of $60.00 and a low of $60.00.

AI Auto Pilots
Is NGNE in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$119.2M
EPS (diluted)
−$5.03
Free cash flow
−$97.5M
Valuation
Market cap
$478.2M
20.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$78.9M
At Sep 30
Shareholder equity
$354.8M
Shares outstanding
20.7M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $0$0FY2023FY2024: $925K$925KFY2024FY2025: $0$0FY2025

From NGNE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated NGNE in the past 90 days, not enough for a consensus
Average 12-month target
$60.00
▲ 159.7% upside

Based on 2 analysts who set a price target on NGNE in the past 90 days. The average target is $60.00, with a high of $60.00 and a low of $60.00, compared with the last close of $23.10.

Low $60.00Avg $60.00High $60.00
Blue marker: last close $23.10
Highest target$60.00
Average target$60.00
Lowest target$60.00
Latest rating changes
HC Wainwright & Co.Target lowered
Nov 10Buy$65 → $60
JP MorganInitiated
Oct 8Buy$60
Canaccord GenuityMaintained
Aug 12Buy$166
GuggenheimMaintained
Aug 12Buy$81
HC Wainwright & Co.Maintained
Aug 12Buy$65
DateFirmActionRatingPrice target
Nov 10HC Wainwright & Co.Target loweredBuy$65 → $60
Oct 8JP MorganInitiatedBuy$60
Aug 12Canaccord GenuityMaintainedBuy$166
Aug 12GuggenheimMaintainedBuy$81
Aug 12HC Wainwright & Co.MaintainedBuy$65
Loading…

Technical Analysis

NGNE · as of the Nov 17 close · updated after every close
Downtrend

The stock is 11% below its 20 day and 20% below its 50 day average. It is 22% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38). The nearest support is the swing low (Oct 23) at $23.08, and the nearest resistance the Pivot R1 at $23.55.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 9.1%/day
Key levels
$43.6652 week high+89.0%
$32.07100 day average+38.8%
$28.22200 day average+22.2%
$27.6150 day average+19.5%
$26.94Swing high (Oct 21)+16.6%
$25.6820 day average+11.2%
$23.55Pivot R1+1.9%
$23.10Last close
$23.08Swing low (Oct 23)−0.1%
$22.87Pivot−1.0%
$22.43Pivot S1−2.9%
$15.9352 week low−31.0%
Indicators
RSI (14)38.49Weak, oversold below 30Neutral
MACD-1.00Below its signal lineBearish
Stochastic9.5Near the bottom of its rangeOversold
ADX (14)15.9No clear trend
Williams %R-90.9Oversold below −80, overbought above −20Oversold
CCI (20)-128.9Oversold below −100, overbought above 100Oversold
Rate of change−13.4%Change over 10 sessionsBearish
ATR (14)$2.11Typical daily range, 9.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NGNE

What happened before

See how NGNE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow NGNE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How NGNE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in NGNE in the last 90 days.

Loading…

See today’s whale options flow across the market →

NGNE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲92 buying vs 34 selling
  • ▲Held by funds +32.2 pts
  • ▲Funds holding +20
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding132112+17.9%
In funds' top 1034−25.0%
Held by funds115.9%83.6%+32.2 pts
New / increased32 / 6022 / 37+55.9%
Reduced / sold out22 / 1231 / 4−2.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NGNE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NGNE is in one of them and how their past NGNE trades turned out.

NGNE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NGNE in an article yet. Here's the latest on the wider market.

About Neurogene

Neurogene is a biotechnology company based in New York that develops genetic medicines for rare neurological diseases. Its lead product candidate, NGN-401, is being studied for Rett syndrome, a severe disease that affects brain development. The company uses its proprietary EXACT technology to control how much therapeutic gene is produced in key areas of the brain. None of its products are approved for sale yet, so it does not currently generate product revenue.

Headquarters
New York, NY